探索靶向治疗类风湿关节炎试验中主要终点的效应:关于核心结局指标集恰当使用的荟萃流行病学研究
该荟萃流行病学研究纳入115项随机对照试验、共55422例类风湿关节炎患者,分析8个核心结局域与ACR 20%应答的关联。实验干预相对对照的ACR 20%应答OR为3.19(95%CI 2.96至3.44)。结论受缺失数据数量与特征显著影响,数据提示疲劳对主要终点可能比既往假设更重要,但基于有限数据。
要点
- 115项试验共55422例患者,实验干预相对对照的ACR 20%应答OR为3.19(95%CI 2.96至3.44)。
- 报告的核心结局域中位数为6个,18项试验仅报告1个域,17项报告全部8个域。
- 单变量荟萃回归中8个核心域均与ACR 20%应答显著相关,身体残疾改善解释力最强;仅纳入报告全部8个域的试验时,疲劳改善解释力最强。
核心结论
- 在该数据集中,关于主要目标的结论明显受到缺失数据的数量与特征影响。
- 数据提示疲劳对主要终点可能比既往假设更重要,但基于有限数据。
研究设计与样本
- 对比较生物制剂及靶向药物与安慰剂或传统改善病情抗风湿药的随机试验进行荟萃流行病学研究。
- 共纳入115项试验、55422例类风湿关节炎患者。
主要发现
- 实验干预相对对照的ACR 20%应答OR为3.19(95%CI 2.96至3.44)。
- 报告的核心结局域中位数为6个;18项试验仅报告1个域,17项报告全部8个域。
- 单变量荟萃回归分析显示8个核心域均与ACR 20%应答显著相关,身体残疾改善解释成功ACR 20%应答最多。
- 仅纳入报告全部8个核心域的试验时,单变量荟萃回归分析证明疲劳改善解释成功ACR 20%应答最多。
关键数值与推荐
- 主要结局指标为ACR 20%应答及现有类风湿关节炎核心结局指标集中至少一个核心域的OR,核心域基于标准化均数差分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 结论明显受到缺失数据的数量与特征影响。
- 关于疲劳对主要终点可能更重要的数据基于有限数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To explore which core domain is best associated with the American College of Rheumatology (ACR) 20% response in trials assessing the effect of targeted interventions in rheumatoid arthritis (RA). METHODS: A meta-epidemiological study was performed on randomised trials investigating biologics and targeted agents compared with placebo or conventional disease-modifying antirheumatic drugs in patients with RA. The main outcome measures were ORs for the ACR 20% response and at least one of the eight core domains according to the existing RA core outcome set (COS) analysed based on standardised mean differences. RESULTS: 115 trials involving 55 422 patients with RA were eligible. The OR for achieving ACR 20% response was 3.19 (95% CI 2.96 to 3.44) for the experimental interventions relative to the comparators. The median number of COS domains reported was 6; 18 trials reported only 1 domain, 17 all 8. Univariable meta-regression analyses indicated that each of the eight core domains was significantly associated with ACR 20% response, yet improvements in physical disability explain a successful ACR 20% response the most. Including only trials reporting on all eight core domains, univariable meta-regression analyses proved improvement in fatigue to explain a successful ACR 20% response the most. CONCLUSIONS: Within this dataset, it is evident that the conclusions concerning our primary objective were significantly influenced by both the amount and characteristics of missing data. Our data suggest that fatigue could be more important for the primary endpoint than previously assumed, but this is based on limited data.
引用
- Lage-Hansen PR, Svendsen N, Kirkham J, et al. Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set. Ann Rheum Dis. 2024. PMID: 38777377. doi:10.1136/ard-2024-225523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。